Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus GP induction chemotherapy versus GP alone for children and adolescents with locoregionally advanced nasopharyngeal carcinoma
ChiCTR2400089865Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete response rate after induction chemotherapy. Started Sep 2024; status: recruiting.
02
Drugs
toripalimabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400089865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089865.